Pharmacy Services
Trimethobenzamide Suppositories - Discontinued Due to Lack of Efficacy
April 9, 2007
The FDA issued a MedWatch alert requiring companies to stop manufacturing and distributing trimethobenzamide hydrochloride suppositories. Manufacturers of trimethobenzamide suppositories must stop shipping product by May 9, 2007. Remaining supplies of this product may be used until depleted. The FDA withdrew approval of trimethobenzamide suppositories due to lack of efficacy data. Oral and injectable trimethobenzamide are not affected and remain available. Marketed names of trimethobenzamide suppositories include Tigan, Tebamide, T-Gen, Trimazide, and Trimethobenz.
Alternative products are available for the treatment of nausea and vomiting in adults and children. Additional information can be found in the links below:
- MedWatch alert:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm152962.htm - FDA Press Release:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108882.htm - Federal Register Notice:
http://www.fda.gov/OHRMS/DOCKETS/98fr/78n-0224-nwl0002.pdf
Updated
April 9, 2007; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.
Social Media
Copyright © 2013 University of Utah Health Care